Form 4: Pure Bioscience Director David Rendall Acquires Stock Options
SEC Form 4 Filing
Director David Rendall reports acquisition of stock options in Pure Bioscience, Inc.
Summary
- On August 20, 2024, David Rendall, a director of Pure Bioscience, Inc., acquired stock options.
- The options grant Rendall the right to buy 125,000 shares of common stock at an exercise price of $0.07 per share.
- The options vest in two tranches: 50% on the earlier of January 15, 2025, or the date of the 2025 annual meeting, and the remaining 50% on the earlier of January 15, 2026, or the date of the 2026 annual meeting.
- The options expire on August 20, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of stock option acquisition. The vesting schedule suggests a long-term commitment from the director.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard Form 4 filing, indicating insider activity. It's common for directors and officers to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/20/2024 | Date of the stock option transaction |
| 01/15/2025 | First possible vesting date for 50% of the options |
| 01/15/2026 | First possible vesting date for the remaining 50% of the options |
| 08/20/2034 | Expiration date of the stock options |
| 08/22/2024 | Date of the form filing |
Keywords
stock options, director, PURE, Pure Bioscience, acquisition, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.